姓名：施文瑜
职称：教授，主任医师
个人简介：江苏南通人，医学博士。
专业研究领域：血液肿瘤、淋巴瘤。
专著与论集：
1） 郑维成，施文瑜＊。SOD1抑制剂诱导DLBCL细胞凋亡。中国实验血液学杂志 2023
2）Yao Wang#, Minan Zhang#, Qingfeng Xue, Huan Zhou, Jie Chen, Hong Wang, Yaping Zhang*, Wenyu Shi*，Case Report: Immune Modulation after PD-1 Inhibitor Therapy in a Patient with Extranodal NK/T-cell Lymphoma Secondary to Chronic Active Epstein-Barr Virus Disease Unveiled by Single-Cell Transcriptomics frontiers in immunology 2023
通讯作者，SCI收录（一区），影响因子：8
3）Xiyue Yan#, Juan Liu#, Yu Ben, Weicheng Zheng, Pan Hu, Yaping Zhang*, Wenyu Shi*，A rare B-myeloid conversion of follicular lymphoma into clonally related acute myeloid leukemia Life (Basel). 2023 Mar 8;13(3):729
通讯作者，SCI收录（三区），影响因子：3.2
4）Chen W, Ni D, Zhang H, Li X, Jiang Y, Wu J, Gu Y, Gao M, Shi W, Song J, Wenyu Shi*，Over-expression of USP15/MMP3 predict poor prognosis and promote growth, migration in non-small cell lung cancer cells Cancer Genet. 2023 Jan 7;272-273:9-15.
通讯作者，SCI收录（四区），影响因子：2.1
5）Jing He＃ , Qingfeng Xue＃，Xin Hua＃ , Quanqing Li，Ziwei Chen, Cindy Zhu and Wenyu Shi*，Association between environmental phenols and all‐cause and cancer mortality Environ Sci Pollut Res Int. 2023 Mar;30(12):33432-37
通讯作者，SCI收录（二区），影响因子：5
6） 刘娟，颜希月，张亚平，施文瑜＊。18F-FDG PET/CT 在黏膜相关淋巴组织淋巴瘤中的临床应用价值。中国临床研究 2022，5（35）649-54
7） Shike Li＃ , Qingfeng Xue＃ and Wenyu Shi*， Primary Osteosarcoma of the Breast: A Rare Case Report and Literature Review, Frontiers in oncology, 2022;12:875793.
通讯作者，SCI收录（二区），影响因子： 5
8） Jing He＃ , Ziwei Chen＃ , Qingfeng Xue＃ , Pingping Sun , Yuan Wang , Cindy Zhu and Wenyu Shi*， Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature Journal of Translational Medicine, 2022;20:186.通讯作者，SCI收录（一区），影响因子： 8
9） Jing He＃ , Ziwei Chen＃ , Qingfeng Xue and Wenyu Shi*， Block of Proliferation Promotes Proliferation, Invasion and Epithelial Mesenchymal Transformation in Gastric Cancer Oxidative Medicine and Cellular Longevity, 2022 Feb 16;2022:2946989.
通讯作者，SCI收录（二区），影响因子： 5
10） Yuan Wang＃, Jing He＃, Manyu Xu, Qingfeng Xue, Cindy Zhu, Juan Liu1, Yaping Zhang＊ and Wenyu Shi*， Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma. Frontiers in oncology, 2022;12:815654.
通讯作者，SCI收录（二区），影响因子： 5
11） Ziwei Chen＃, Jing He＃and Wenyu Shi*， Association between urinary environmental phenols and the prevalence of cardiovascular diseases in US adults Environmental Science and Pollution Research, 2022; Jan 29.
通讯作者，SCI收录（二区），影响因子： 4
12） Weicheng Zheng＃，Qingfeng Xue＃, Xueping Sha＃, Yao Wang, Yuan Wang, Juan Liu, Yaping Zhang＊, Wenyu Shi＊ Successful PD-1 Inhibitor Treatment in a Patient With Refractory Transformed Follicular Lymphoma Who Failed to Respond to CAR-T Cell Therapy: A Case Report Journal of Cancer Research and Clinical Oncology. Cancer Biology & Therapy, 2021 Dec 2;22(10-12):537-543.
通讯作者，SCI收录（三区），影响因子： 3
13） Wei Wang＃, Qianqian Wu＃, Ziheng Wang＃, Shiqi Ren, Hanyu Shen, Wenyu Shi＊ and Yunzhao Xu*，Development of a Prognostic Model for Ovarian Cancer Patients Based on Novel Immune Microenvironment Related Genes. Frontiers in oncology, 2021;11:647273.
共同通讯作者，SCI收录（二区），影响因子： 6.2
14） Pan Hu＃，YuBen＃，Juan Liu，Weicheng Zheng，Xiyue Yan，Yaping Zhang＊， Wenyu Shi＊ Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report OncoTargets and Therapy. 2021:14 2489–2495
通讯作者，SCI收录（三区），影响因子： 4.08
15） Yunzhao Xu＃， Wei Wang＃，Shuting Gu， Qinqin Liu，Jinling Chen， Haixia Mao， Yuanlin Liu，Qinghua Xi＊，Wenyu Shi＊ High neuropilin and tolloid-like expression associated with metastasis and poor survival in epithelial ovarian cancer via regulation of actin cytoskeleton. J Cell Mol Med 2020;24:9114–9124.
通讯作者，SCI收录（二区），影响因子： 4.08
16） Hong Zhou＃, Pan Hu＃, Xiyue Yan, Yaping Zhang＊, and Wenyu Shi＊. Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects. OncoTargets and Therapy. 2020:13 4877–4892
通讯作者，SCI收录（三区），影响因子： 3.08
17）Hong Zhou＃, Li Yang＃, Qingxiu Dang, Jianfei Huang, Yuehua Cheng, Yaping Zhang＊, and Wenyu Shi＊. Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma. Cancer Biol Ther. 2020 Apr 2;21(4):303-308
通讯作者，SCI收录（三区），影响因子： 3.29
18）Bhawana George＃, Suraj Konnath George＃, Wenyu Shi＃, Abedul Haque, Ping Shi, Ghazaleh Eskandari, Magnus Axelson, Olle Larsson, Ahmed O. Kaseb, Hesham M. Amin＊. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2019 Jul 24;12(1):80. 共同第一作者，SCI收录（一区），影响因子： 11.3
19）Qingxiu Dang＃, Lili Chen＃, Mengqi Xu＃, Xuefen You, Hong Zhou, Yaping Zhang＊, Wenyu Shi＊， The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome T inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis. Cellular Signalling 2019 (59):76-84. 通讯作者，通讯作者，SCI收录（二区），影响因子： 3.5
20）Qingxiu Dang＃, Hong Zhou＃, Juan Qian＃, Li Yang, Jianfei Huang, Yaping Zhang＊, Wenyu Shi＊. LAMP1 Overexpression Predicts Poor Prognosis in Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 2018 Nov;18(11):749 通讯作者，SCI收录（三区），影响因子： 2.5
21）Yaping Zhang＃, Xinfeng Wang＃, Yifei Liu, Chunfeng Sun, Wenyu Shi＊, Hongming Huang＊. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review. Cancer Biol Ther. 2018 Jul 3;19(7):549-553.
共同通讯作者，SCI收录（三区），影响因子： 3.29
国际学术会议报告：
1） Wenyu Shi，Yuan Wang, Yaping Zhang, Haixia Cao and Guangcan Gao. Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for DLBCL在2023年欧洲血液学年会进行报告，摘要已被会议收录
2） Wenyu Shi， Hong Zhou， Yaping Zhang， Jianfei Huang， Pan Hu， Jianyong Li. GSK1838705a, an IGF-1R/ALK inhibitor, overcomes crizotinib resistance in ALK+ALCL在2019年美国61届血液学年会进行报告，摘要已被Blood收录
3） Wenyu Shi＃， Qingxiu Dang, Hong Zhou, Juan Qian, Yaping Zhang. LAMP1 Overexpression Predicts Poor Prognosis in Diffuse Large B Cell Lymphoma 在2017年香港李嘉诚澳门永利集团3044郑裕彤奖学金学术报告会壁报交流
主要科研项目
主持多项省部级以上科研项目，其中包括国家自然科学基金项目2项。
讲授课程
肿瘤学进展
指导研究生情况
已毕业硕士生9名；在读博士生3名，硕士生13名。
